The findings of the phase-three clinical trial highlighted a 40% reduction in the risk of death from cervical cancer and a 35% reduction in recurrence rates over five years. This trial, which drew patients from multiple countries including the UK and Mexico, marks a significant leap in treatment.
Dr. Mary McCormack emphasized that this discovery is the most significant breakthrough in cervical cancer treatment since the late 20th century, representing a crucial advancement in patient survival and quality of life.
Collection
[
|
...
]